
Why The $101 Million XPRIZE Could Redefine Human Healthspan
Show notes
Guest:
Jamie Justice, Ph.D.
Executive Director, XPRIZE Healthspan and Vice President of the Health Domain at XPRIZE Foundation
LinkedIn: https://www.linkedin.com/in/jamie-justice-ph-d-6b933146/
Website: https://www.xprize.org/
Steven R. Cummings, MD
Executive Director at S.F. Coordinating Center (SFCC) in the CPMC Research Institute
LinkedIn: https://www.linkedin.com/in/steve-cummings-71668514a/
Website: https://www.xprize.org/people/steve-cummings
_______________
What if the breakthrough longevity needs isn’t another intervention, but a better way to prove what works?
Phil Newman sits down with XPRIZE Healthspan director Jamie Justice and judging chair Professor Steven Cummings to explore the $101 million competition.
Together they explain why muscle, cognitive and immune function form its evidence framework, and how one-year trials could help model longer-term healthspan gains. From repurposed drugs to gene therapies, finalists must demonstrate measurable effects under common standards.
They also discuss FDA pathways, scalability, safety and prevention versus reversal.
In this episode, you'll learn:
- How finalists are judged
- Why function matters beyond biomarkers
- How trials model 10–20 years of decline
- Why scalability matters
- Why safety could determine success
If you want to understand how longevity interventions could become credible medicine, this episode connects rigorous trials with real-world healthspan.
Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
_______________
Host:
Phil Newman: https://qrco.de/bgXpNY